Predicting chemo response in children with hepatoblastoma
Part of Cancer clinical trials.
This trial tests a new way to see if chemotherapy will work for children with hepatoblastoma, a type of liver cancer. It uses a blood test (ctDNA 5hmc) to help predict treatment success and monitor if the cancer comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have hepatoblastoma (a liver cancer) confirmed by a biopsy.
- You must be under 18 years old.
- Your parent or guardian must agree to the study and sign a consent form.
- You cannot have a different or returning cancer.
- You cannot have had chemotherapy or radiation to the belly for another tumor.
- You cannot have serious heart, brain, or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests a modified treatment plan for children newly diagnosed with hepatoblastoma, a type of liver cancer. It may help improve how well treatment works and how safely it can be given by using a structured approach.
This trial tests a combination of an immunotherapy (pucotenlimab), a targeted therapy (lenvatinib), and chemotherapy for children with advanced or relapsed hepatoblastoma that hasn't responded to prior treatment. The goal is to see if this combination can help shrink or control the tumor.
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.
This study uses a 3D-printed model of your liver tumor to help doctors choose treatment that may prevent the cancer from coming back after surgery. The model predicts how your tumor might respond, so you get the most effective therapy.
This study is looking at people with advanced liver cancer (HCC) that cannot be removed by surgery. Researchers want to see if certain markers in your blood or tumor can help predict how well you respond to a combination of chemotherapy delivered directly to the liver and immunotherapy. If you join, you will receive the planned treatment and provide additional blood and tissue samples for analysis.
Hear when a new Hepatoblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.